Skip to content
value.today

PolyPid Ltd.: peers

Change the peers

PolyPid Ltd. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

PolyPid Ltd., Sol-Gel Technologies, Mediwound, Compugen Ltd., Intercure Ltd., Solegreen Ltd, Nasus Pharma Ltd.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

PolyPid Ltd., Sol-Gel Technologies, Mediwound, Compugen Ltd., Oramed Pharmaceuticals Inc., Intercure Ltd., Solegreen Ltd, Nasus Pharma Ltd. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasurePolyPid Ltd.base
PYPD · 🇮🇱 IL
Percentile in Healthcare
Percentile in Israel
Sol-Gel Technologies
4SG.F · 🇮🇱 IL
Percentile in Healthcare
Percentile in Israel
Mediwound
M8W.F · 🇮🇱 IL
Percentile in Healthcare
Percentile in Israel
Compugen Ltd.
CGEN.TA · 🇮🇱 IL
Percentile in Healthcare
Percentile in Israel
Oramed Pharmaceuticals Inc.
ORMP · 🇮🇱 IL
Percentile in Healthcare
Percentile in Israel
Intercure Ltd.
INCR · 🇮🇱 IL
Percentile in Healthcare
Percentile in Israel
Solegreen Ltd
SLGN.TA · 🇮🇱 IL
Percentile in Healthcare
Percentile in Israel
Nasus Pharma Ltd.
NSRX · 🇮🇱 IL
Percentile in Healthcare
Percentile in Israel
Group median
Size
Market cap (Better neither way: ranked highest first)$103 MAug 1, 2026 · Market data3rd of 8$99 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one5th of 8$88 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one6th of 8$174 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 8$177 MOct 27, 2026 · Market data1st of 8$51 MAug 1, 2026 · Market data7th of 8$103 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8$45 MAug 1, 2026 · Market data8th of 8$101 M8 ranked
Revenue (Better neither way: ranked highest first)——$19 MFY2025 · SEC4th of 6$17 MFY2025 · SEC5th of 6$73 MFY2025 · SEC2nd of 6$2 MFY2025 · SEC6th of 6$65 MFY2024 · SEC3rd of 6——$1.2 BFY2025 · SEC1st of 6$42 M6 ranked
Net income (Higher is better)$-34 MFY2025 · SEC7th of 7$-6 MFY2025 · SEC4th of 7$-24 MFY2025 · SEC6th of 7$35 MFY2025 · SEC2nd of 7$64 MFY2025 · SEC1st of 7$-18 MFY2024 · SEC5th of 7——$-6 MFY2025 · SEC3rd of 7$-6 M7 ranked
Employees (Better neither way: ranked highest first)59December 31, 2025 · Profileonly one with it——————————————59—
Growth
Revenue growth (Higher is better)————+68.0%FY2025 · SEC2nd of 488th89th-16.1%FY2025 · SEC3rd of 411th13th+161.2%FY2025 · SEC1st of 495th95th————-33.0%FY2024 · SEC4th of 47th4th————————+25.9%4 ranked
Revenue growth, 3 years a year (Higher is better)————+71.0%FY2025 · SEC2nd of 493rd95th-13.8%FY2025 · SEC4th of 410th12th+113.3%FY2025 · SEC1st of 496th99th————-1.7%FY2024 · SEC3rd of 423rd27th————————+34.6%4 ranked
Earnings per share growth (Higher is better)-57.4%FY2025 · SEConly one with it7th16th————————————————————————————-57.4%—
Margins and returns
Gross margin (Higher is better)————————19.2%FY2025 · SEC2nd of 48th20th87.3%FY2025 · SEC1st of 489th98th0.5%FY2025 · SEC4th of 42nd8th12.7%FY2024 · SEC3rd of 45th11th————————15.9%4 ranked
Operating margin (Higher is better)————-38.9%FY2025 · SEC4th of 634th31st-149.0%FY2025 · SEC5th of 619th20th43.1%FY2025 · SEC1st of 698th98th-754.5%FY2025 · SEC6th of 62nd4th-28.1%FY2024 · SEC3rd of 639th34th————-0.4%FY2025 · SEC2nd of 657th47th-33.5%6 ranked
Net margin (Higher is better)————-31.6%FY2025 · SEC4th of 537th33rd-140.8%FY2025 · SEC5th of 519th18th48.6%FY2025 · SEC1st of 598th99th————-28.4%FY2024 · SEC3rd of 539th34th————-0.5%FY2025 · SEC2nd of 559th49th-28.4%5 ranked
Free cash flow margin (Higher is better)————1.4%FY2025 · SEC2nd of 655th46th-127.5%FY2025 · SEC5th of 619th20th43.0%FY2025 · SEC1st of 698th99th-457.5%FY2025 · SEC6th of 67th5th-29.9%FY2024 · SEC4th of 633rd34th————-0.4%FY2025 · SEC3rd of 651st44th-15.1%6 ranked
Return on equity (Higher is better)-366.4%FY2025 · SEC6th of 63rd2nd-23.7%FY2025 · SEC4th of 659th42nd-63.9%FY2025 · SEC5th of 636th32nd44.8%FY2025 · SEC1st of 697th99th37.0%FY2025 · SEC2nd of 696th97th-15.6%FY2024 · SEC3rd of 663rd44th————————-19.7%6 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————————————————2.8×price Oct 27, 2026 · Market dataonly one with it3rd—————————————2.8×—
Price to sales (Better neither way: ranked highest first)————————————————88.7×price Oct 27, 2026 · Market dataonly one with it94th96th0.8×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————0.0×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price88.7×—
Price to book (Better neither way: ranked highest first)9.4×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————————————0.9×price Oct 27, 2026 · Market dataonly one with it17th41st0.5×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————16.3×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price0.9×—
Free cash flow yield (Higher is better)-27.2%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————————————-5.2%price Oct 27, 2026 · Market dataonly one with it54th38th-37.4%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————-10.9%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price-5.2%—
Financial strength
Debt to equity (Lower is better)————————————————————0.3×FY2024 · SEConly one with it38th75th————————0.3×—
Scorecard
Scorecard (Higher is better)2 of 8FY2025 · Scorecard5th of 78 of 14FY2025 · Scorecard3rd of 70 of 12FY2025 · Scorecard7th of 711 of 14FY2025 · Scorecard1st of 711 of 19FY2025 · Scorecard2nd of 72 of 13FY2024 · Scorecard6th of 7——2 of 6FY2025 · Scorecard4th of 733% passed7 ranked
Valuation checks (Higher is better)————————3 of 5FY2025 · Scorecardonly one with it——————60% passed—
Growth checks (Higher is better)1 of 2FY2025 · Scorecard4th of 74 of 6FY2025 · Scorecard3rd of 70 of 6FY2025 · Scorecard5th of 76 of 6FY2025 · Scorecard1st of 72 of 2FY2025 · Scorecard1st of 70 of 6FY2024 · Scorecard5th of 7——0 of 1FY2025 · Scorecard5th of 750% passed7 ranked
Profitability checks (Higher is better)0 of 3FY2025 · Scorecard6th of 72 of 5FY2025 · Scorecard4th of 70 of 5FY2025 · Scorecard6th of 74 of 5FY2025 · Scorecard1st of 73 of 5FY2025 · Scorecard2nd of 71 of 5FY2024 · Scorecard5th of 7——1 of 2FY2025 · Scorecard3rd of 740% passed7 ranked
Financial health checks (Higher is better)1 of 2FY2025 · Scorecard2nd of 71 of 2FY2025 · Scorecard2nd of 70 of 1FY2025 · Scorecard7th of 71 of 2FY2025 · Scorecard2nd of 72 of 3FY2025 · Scorecard1st of 71 of 2FY2024 · Scorecard2nd of 7——1 of 2FY2025 · Scorecard2nd of 750% passed7 ranked
Shareholder returns checks (Higher is better)0 of 1FY2025 · Scorecard3rd of 51 of 1FY2025 · Scorecard1st of 5——0 of 1FY2025 · Scorecard3rd of 51 of 4FY2025 · Scorecard2nd of 5————0 of 1FY2025 · Scorecard3rd of 50% passed5 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)10.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4——————42.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 41.2%2026-Q2 · 13F4th of 4——24.1%2026-Q1 · 13F2nd of 417.4%4 ranked
Institutions holding (Better neither way: ranked highest first)252026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4——————932026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4162026-Q2 · 13F3rd of 4——92026-Q1 · 13F4th of 4214 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)-3.2 pp2026-Q2 against 2026-Q1 · 13F3rd of 3——————+7.6 pp2026-Q2 against 2026-Q1 · 13F2nd of 3————+24.1 pp2026-Q1 against 2025-Q4 · 13F1st of 3+7.6 pp3 ranked
Dividends
Shareholder yield (Higher is better)————————————————2.7%FY2025 · SEConly one with it56th—————————————2.7%—
Dividend per share (Better neither way: ranked highest first)————————$0.25FY2025 · SEConly one with it——————$0.25—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = PolyPid Ltd.: How market caps are worked out; Sol-Gel Technologies: How market caps are worked out; Mediwound: How market caps are worked out; Compugen Ltd.: How market caps are worked out; Oramed Pharmaceuticals Inc.: How market caps are worked out; Intercure Ltd.: How market caps are worked out; Solegreen Ltd: How market caps are worked out; Nasus Pharma Ltd.: How market caps are worked out.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
PolyPid Ltd.———
Sol-Gel Technologies-38.9%FY2025
34th percentile in Healthcaremedian -7.7%, 674 companies
31st percentile in Israelmedian -0.2%, 67 companies
Mediwound-149.0%FY2025
19th percentile in Healthcaremedian -7.7%, 674 companies
20th percentile in Israelmedian -0.2%, 67 companies
Compugen Ltd.43.1%FY2025
98th percentile in Healthcaremedian -7.7%, 674 companies
98th percentile in Israelmedian -0.2%, 67 companies
Oramed Pharmaceuticals Inc.-754.5%FY2025
2nd percentile in Healthcaremedian -7.7%, 674 companies
4th percentile in Israelmedian -0.2%, 67 companies
Intercure Ltd.-28.1%FY2024
39th percentile in Healthcaremedian -7.7%, 674 companies
34th percentile in Israelmedian -0.2%, 67 companies
Solegreen Ltd———
Nasus Pharma Ltd.-0.4%FY2025
57th percentile in Healthcaremedian -7.7%, 674 companies
47th percentile in Israelmedian -0.2%, 67 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$309 M$618 M$926 M$1.2 B20102012201420162018202020222024Sol-Gel Technologies $19 MMediwound $17 MCompugen Ltd. $73 MOramed Pharmaceuticals Inc. $2 MIntercure Ltd. $65 M

Rank in the group

1st2nd3rd4th5th20152016201720182019202020212022202320242025Sol-Gel Technologies: 3rd of 3 in 2017Sol-Gel Technologies: 4th of 4 in 2018Sol-Gel Technologies: 2nd of 4 in 2019Sol-Gel Technologies: 3rd of 5 in 2020Sol-Gel Technologies: 2nd of 5 in 2021Sol-Gel Technologies: 4th of 5 in 2022Sol-Gel Technologies: 4th of 5 in 2023Sol-Gel Technologies: 4th of 4 in 2024Sol-Gel Technologies: 3rd of 5 in 2025Sol-Gel TechnologiesMediwound: 2nd of 2 in 2015Mediwound: 1st of 2 in 2016Mediwound: 1st of 3 in 2017Mediwound: 2nd of 4 in 2018Mediwound: 1st of 4 in 2019Mediwound: 1st of 5 in 2020Mediwound: 3rd of 5 in 2021Mediwound: 2nd of 5 in 2022Mediwound: 3rd of 5 in 2023Mediwound: 3rd of 4 in 2024Mediwound: 4th of 5 in 2025MediwoundCompugen Ltd.: 1st of 2 in 2015Compugen Ltd.: 1st of 4 in 2018Compugen Ltd.: 5th of 5 in 2020Compugen Ltd.: 4th of 5 in 2021Compugen Ltd.: 3rd of 5 in 2022Compugen Ltd.: 2nd of 5 in 2023Compugen Ltd.: 2nd of 4 in 2024Compugen Ltd.: 2nd of 5 in 2025Compugen Ltd.Oramed Pharmaceuticals Inc.: 2nd of 2 in 2016Oramed Pharmaceuticals Inc.: 2nd of 3 in 2017Oramed Pharmaceuticals Inc.: 3rd of 4 in 2018Oramed Pharmaceuticals Inc.: 3rd of 4 in 2019Oramed Pharmaceuticals Inc.: 4th of 5 in 2020Oramed Pharmaceuticals Inc.: 5th of 5 in 2021Oramed Pharmaceuticals Inc.: 5th of 5 in 2022Oramed Pharmaceuticals Inc.: 5th of 5 in 2023Oramed Pharmaceuticals Inc.: 5th of 5 in 2025Oramed Pharmaceuticals IncIntercure Ltd.: 4th of 4 in 2019Intercure Ltd.: 2nd of 5 in 2020Intercure Ltd.: 1st of 5 in 2021Intercure Ltd.: 1st of 5 in 2022Intercure Ltd.: 1st of 5 in 2023Intercure Ltd.: 1st of 4 in 2024Intercure Ltd.Nasus Pharma Ltd.: 1st of 5 in 2025Nasus Pharma Ltd.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearPolyPid Ltd.Sol-Gel TechnologiesMediwoundCompugen Ltd.Oramed Pharmaceuticals Inc.Intercure Ltd.Solegreen LtdNasus Pharma Ltd.
2025—$19 MSEC3rd$17 MSEC4th$73 MSEC2nd$2 MSEC5th——$1.2 BSEC1st
2024—$12 MSEC4th$20 MSEC3rd$28 MSEC2nd—$65 MSEC1st——
2023—$2 MSEC4th$19 MSEC3rd$33 MSEC2nd$1 MSEC5th$96 MSEC1st——
2022—$4 MSEC4th$27 MSEC2nd$8 MSEC3rd$3 MSEC5th$116 MSEC1st——
2021—$31 MSEC2nd$24 MSEC3rd$6 MSEC4th$3 MSEC5th$68 MSEC1st——
2020—$9 MSEC3rd$22 MSEC1st$2 MSEC5th$3 MSEC4th$19 MSEC2nd——
2019—$23 MSEC2nd$32 MSEC1st—$3 MSEC3rd$3 MSEC4th——
2018—$0 MSEC4th$3 MSEC2nd$18 MSEC1st$2 MSEC3rd———
2017—$0 MSEC3rd$3 MSEC1st—$2 MSEC2nd———
2016——$2 MSEC1st—$1 MSEC2nd———
2015——$1 MSEC2nd$9 MSEC1st————
2014———$12 MSEC————

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of PolyPid Ltd.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Sol-Gel Technologies4SG.F · 🇮🇱 Israel
    Same industry: Biotechnology · Similar size: $99 M market cap against $103 M · Same country: Israel · Ratios of the last two fiscal years on file
    Market cap $99 M (last known, Jul 30, 2023) · revenue $19 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • MediwoundM8W.F · 🇮🇱 Israel
    Same industry: Biotechnology · Similar size: $88 M market cap against $103 M · Same country: Israel · Ratios of the last two fiscal years on file
    Market cap $88 M (last known, Jul 30, 2023) · revenue $17 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Compugen Ltd.CGEN.TA · 🇮🇱 Israel
    Same industry: Biotechnology · Similar size: $174 M market cap against $103 M · Same country: Israel · Ratios of the last two fiscal years on file
    Market cap $174 M (last known, Jan 5, 2024) · revenue $73 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • Oramed Pharmaceuticals Inc.ORMP · 🇮🇱 Israel
    Same industry: Biotechnology · Similar size: $177 M market cap against $103 M · Same country: Israel · Ratios of the last two fiscal years on file
    Market cap $177 M (Oct 27, 2026) · revenue $2 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • Intercure Ltd.INCR · 🇮🇱 Israel
    Same industry: Biotechnology · Similar size: $51 M market cap against $103 M · Same country: Israel · Ratios of the last two fiscal years on file
    Market cap $51 M (Aug 1, 2026) · revenue $65 M (year to December 2024)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    In the group
  • Solegreen LtdSLGN.TA · 🇮🇱 Israel
    Same industry: Biotechnology · Similar size: $103 M market cap against $103 M · Same country: Israel
    Market cap $103 M (last known, Jan 5, 2024)
    95 of 100 (industry or sector 50 + size 30 + country 15)
    In the group
  • Nasus Pharma Ltd.NSRX · 🇮🇱 Israel
    Same industry: Biotechnology · Similar size: $45 M market cap against $103 M · Same country: Israel · Ratios of the last two fiscal years on file
    Market cap $45 M (Aug 1, 2026) · revenue $1.2 B (year to December 2025)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    In the group
  • Protalix BioTherapeutics, Inc.PLX.TA · 🇮🇱 Israel
    Same industry: Biotechnology · Similar size: $59 M market cap against $103 M · Same country: Israel
    Market cap $59 M (last known, Dec 25, 2022) · revenue $53 M (year to December 2025)
    91 of 100 (industry or sector 50 + size 26 + country 15)
    + Add
  • Pluristem TherapeuticsPSTI.TA · 🇮🇱 Israel
    Same industry: Biotechnology · Similar size: $46 M market cap against $103 M · Same country: Israel
    Market cap $46 M (last known, Jan 7, 2022)
    90 of 100 (industry or sector 50 + size 25 + country 15)
    + Add
  • Enlivex TherapeuticsENLV.TA · 🇮🇱 Israel
    Same industry: Biotechnology · Similar size: $44 M market cap against $103 M · Same country: Israel
    Market cap $44 M (last known, Jul 30, 2023)
    89 of 100 (industry or sector 50 + size 24 + country 15)
    + Add
  • Entera Bio Ltd.ENTX · 🇮🇱 Israel
    Same industry: Biotechnology · 5.3× larger by market cap · Same country: Israel · Ratios of the last two fiscal years on file
    Market cap $543 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    89 of 100 (industry or sector 50 + size 19 + country 15 + figures on file 5)
    + Add
  • Pluri Inc.PLUR · 🇮🇱 Israel
    Same industry: Biotechnology · 6.8× smaller by market cap · Same country: Israel · Ratios of the last two fiscal years on file
    Market cap $15 M (Oct 29, 2026) · revenue $1 M (year to June 2026)
    88 of 100 (industry or sector 50 + size 18 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.